Head-to-head · WeighScore
Direct Meds vs Fierce Health
The verdict
Direct Meds takes it — 82.6/100 to 56.6/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Direct Meds | Fierce Health |
|---|---|---|
| WeighScore | 82.6/100 | 56.6/100 |
| Grade | B− | C |
| Scorecard rank | #19 | #410 |
| Semaglutide | $179/mo | $297/mo (3-month plan, compounded) |
| Tirzepatide | $224/mo | $497/mo (3-month plan, compounded) |
| Coverage | Not publicly listed | 30 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #19 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.